JP2009544280A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544280A5 JP2009544280A5 JP2009519713A JP2009519713A JP2009544280A5 JP 2009544280 A5 JP2009544280 A5 JP 2009544280A5 JP 2009519713 A JP2009519713 A JP 2009519713A JP 2009519713 A JP2009519713 A JP 2009519713A JP 2009544280 A5 JP2009544280 A5 JP 2009544280A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- deletion
- cfhr1
- gene product
- cfhr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 53
- 238000012217 deletion Methods 0.000 claims description 25
- 230000037430 deletion Effects 0.000 claims description 25
- 108010053085 Complement Factor H Proteins 0.000 claims description 21
- 102100035432 Complement factor H Human genes 0.000 claims description 21
- 101150083730 CFHR1 gene Proteins 0.000 claims description 18
- 101150077755 CFHR3 gene Proteins 0.000 claims description 18
- 208000002780 macular degeneration Diseases 0.000 claims description 18
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 17
- 102100040132 Complement factor H-related protein 1 Human genes 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 101000890732 Homo sapiens Complement factor H-related protein 1 Proteins 0.000 claims description 14
- 102100035321 Complement factor H-related protein 3 Human genes 0.000 claims description 13
- 101000878136 Homo sapiens Complement factor H-related protein 3 Proteins 0.000 claims description 13
- 102100035324 Complement factor H-related protein 4 Human genes 0.000 claims description 9
- 101000878133 Homo sapiens Complement factor H-related protein 4 Proteins 0.000 claims description 9
- 210000000349 chromosome Anatomy 0.000 claims description 9
- 102220005747 rs1061170 Human genes 0.000 claims description 8
- 102200031793 rs800292 Human genes 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 6
- 102220130916 rs1061147 Human genes 0.000 claims description 6
- 101150030967 CFH gene Proteins 0.000 claims description 5
- 239000000523 sample Substances 0.000 claims description 5
- 101150003288 C2 gene Proteins 0.000 claims description 4
- 108700026244 Open Reading Frames Proteins 0.000 claims description 4
- 102200031710 rs121913059 Human genes 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 108020005544 Antisense RNA Proteins 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 108091026890 Coding region Proteins 0.000 claims description 2
- 102000004381 Complement C2 Human genes 0.000 claims description 2
- 108090000955 Complement C2 Proteins 0.000 claims description 2
- 102000003712 Complement factor B Human genes 0.000 claims description 2
- 108090000056 Complement factor B Proteins 0.000 claims description 2
- 102220500353 Complement factor B_L9H_mutation Human genes 0.000 claims description 2
- 102220500344 Complement factor B_R32Q_mutation Human genes 0.000 claims description 2
- 101150007028 HTRA1 gene Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000003184 complementary RNA Substances 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 102220005751 rs2274700 Human genes 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 208000019553 vascular disease Diseases 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 206010002329 Aneurysm Diseases 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 2
- 101150015741 CFHR4 gene Proteins 0.000 description 2
- 102000014447 Complement C1q Human genes 0.000 description 2
- 108010078043 Complement C1q Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700028909 Serum Amyloid A Proteins 0.000 description 2
- 102000054727 Serum Amyloid A Human genes 0.000 description 2
- -1 cellotraferrin Proteins 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102100025007 14-3-3 protein epsilon Human genes 0.000 description 1
- 101710125124 14-3-3 protein epsilon Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 102100029335 Beta-crystallin A2 Human genes 0.000 description 1
- 101710189776 Beta-crystallin A2 Proteins 0.000 description 1
- 102100029334 Beta-crystallin A3 Human genes 0.000 description 1
- 101710189781 Beta-crystallin A3 Proteins 0.000 description 1
- 102100030504 Beta-crystallin A4 Human genes 0.000 description 1
- 101710189772 Beta-crystallin A4 Proteins 0.000 description 1
- 102100029968 Calreticulin Human genes 0.000 description 1
- 108090000549 Calreticulin Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010028773 Complement C5 Proteins 0.000 description 1
- 108010027644 Complement C9 Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101710176517 EGF-containing fibulin-like extracellular matrix protein 1 Proteins 0.000 description 1
- 102100031814 EGF-containing fibulin-like extracellular matrix protein 1 Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 102100020903 Ezrin Human genes 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102100039326 Gamma-crystallin S Human genes 0.000 description 1
- 101710092831 Gamma-crystallin S Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 102000018866 Hyaluronan Receptors Human genes 0.000 description 1
- 108010013214 Hyaluronan Receptors Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 101100341510 Mus musculus Itgal gene Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 108010053763 Pyruvate Carboxylase Proteins 0.000 description 1
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 description 1
- 108010045517 Serum Amyloid P-Component Proteins 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 108010055671 ezrin Proteins 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 108010017007 glucose-regulated proteins Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83101806P | 2006-07-13 | 2006-07-13 | |
| US60/831,018 | 2006-07-13 | ||
| US84007306P | 2006-08-23 | 2006-08-23 | |
| US60/840,073 | 2006-08-23 | ||
| PCT/US2007/073514 WO2008008986A2 (en) | 2006-07-13 | 2007-07-13 | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009544280A JP2009544280A (ja) | 2009-12-17 |
| JP2009544280A5 true JP2009544280A5 (enExample) | 2010-09-02 |
| JP5431151B2 JP5431151B2 (ja) | 2014-03-05 |
Family
ID=38924245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009519713A Active JP5431151B2 (ja) | 2006-07-13 | 2007-07-13 | 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US7867727B2 (enExample) |
| EP (3) | EP2447275B1 (enExample) |
| JP (1) | JP5431151B2 (enExample) |
| AT (1) | ATE551350T1 (enExample) |
| AU (1) | AU2007272335B2 (enExample) |
| CA (1) | CA2659392A1 (enExample) |
| DK (1) | DK2447275T3 (enExample) |
| IL (1) | IL196319A0 (enExample) |
| NZ (1) | NZ574046A (enExample) |
| SG (1) | SG173371A1 (enExample) |
| WO (1) | WO2008008986A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2357257B1 (en) | 2005-02-14 | 2019-07-31 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
| US8012683B2 (en) | 2006-02-13 | 2011-09-06 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
| US20080146501A1 (en) * | 2006-02-13 | 2008-06-19 | University Of Iowa Research Foundation | Protective complement proteins and age-related macular degeneration |
| MX2009000909A (es) * | 2006-07-26 | 2009-02-04 | Univ Yale | Diagnostico y tratamiento de degeneracion macular relacionada con la edad. |
| CA2704809A1 (en) * | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Rca locus analysis to assess susceptibility to amd and mpgnii |
| US20090186370A1 (en) * | 2008-01-18 | 2009-07-23 | Ogle Matthew F | Diagnostic biomarkers for vascular aneurysm |
| DE102008049136B4 (de) * | 2008-09-26 | 2012-10-25 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. | Neue Regulatoren des angeborenen Immunsystems |
| JP2012533562A (ja) * | 2009-07-16 | 2012-12-27 | グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド | 治療法 |
| WO2011017229A2 (en) * | 2009-08-06 | 2011-02-10 | Tufts - New England Medical Center | Plasma complement components as expression markers for age-related macular degeneration and related phenotypes |
| WO2011029954A2 (de) * | 2009-09-14 | 2011-03-17 | Mosaiques Diagnostics And Therapeutics Ag | Polypeptidmarker zur diagnostik und beurteilung vaskulärer erkrankungen |
| JP5706612B2 (ja) * | 2009-12-28 | 2015-04-22 | 学校法人 埼玉医科大学 | 加齢黄斑変性症易罹患性の判定マーカー並びに判定方法及び判定キット |
| WO2012051462A2 (en) * | 2010-10-14 | 2012-04-19 | Sequenom, Inc. | Complement factor h copy number variants found in the rca locus |
| WO2012112955A2 (en) * | 2011-02-17 | 2012-08-23 | The Trustees Of Columbia University In The City Of New York | Methods for identifying subjects with a genetic risk for developing iga nephropathy |
| CN103874526A (zh) * | 2011-04-29 | 2014-06-18 | 犹他大学研究基金会 | 预测补体介导的疾病的发展的方法 |
| JP2013064616A (ja) * | 2011-09-15 | 2013-04-11 | Osaka Univ | 高度動脈硬化を発症している可能性を検出する方法およびその利用 |
| WO2013150132A2 (de) * | 2012-04-05 | 2013-10-10 | Mosaiques Diagnostics And Therapeutics Ag | Polypeptidmarker zur diagnostik und beurteilung von schlaganfällen |
| GB201301632D0 (en) * | 2013-01-30 | 2013-03-13 | Imp Innovations | Complement System |
| EP2962106A1 (en) * | 2013-02-26 | 2016-01-06 | Roche Diagnostics GmbH | Agents, kits and methods for complement factor h-related protein 1 detection |
| US10202647B2 (en) | 2013-04-12 | 2019-02-12 | The Trustees Of Columbia University In The City Of New York | Mutations in DSTYK cause dominant urinary tract malformations |
| WO2014194213A1 (en) * | 2013-05-30 | 2014-12-04 | University Of Iowa Research Foundation | Specific complement proteins and efficacy of antibody therapy |
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| JP7199966B2 (ja) | 2015-12-23 | 2023-01-06 | ソルボンヌ ウニベルシテ | ＣＤ１１ｂ／ＣＤ１８に対するＣＦＨの結合を阻害する薬剤、およびその使用 |
| US11142548B2 (en) | 2016-05-10 | 2021-10-12 | Sorbonne Universite | Agents that activate CD47 and their use in the treatment of inflammation |
| WO2019215330A1 (en) * | 2018-05-10 | 2019-11-14 | The University Of Manchester | Methods for assessing macular degeneration |
| EP3824095A4 (en) | 2018-07-20 | 2022-04-20 | University of Utah Research Foundation | GENE THERAPY FOR MACULATE GENERATION |
| DE102018120016B4 (de) | 2018-08-16 | 2020-09-03 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- | Modulatoren der Funktion von Faktor H-verwandtem Protein 1 und deren Verwendungen in der Kontrolle von Entzündung |
| US20220146530A1 (en) * | 2019-03-07 | 2022-05-12 | Reti Mark Co., Ltd. | A combination of biomarkers for diagnosing of age-related macular degeneration and use thereof |
| CN113966401A (zh) | 2019-04-10 | 2022-01-21 | 犹他大学研究基金会 | 用于治疗amd的htra1调节 |
| KR20230019062A (ko) * | 2019-10-22 | 2023-02-07 | 어플라이드 제네틱스 테크놀로지스 코퍼레이션 | 연령-관련 황반 변성 및 다른 안구 질환 및 장애의 치료를 위한 아데노-연관 바이러스 (aav) 벡터 |
| EP4214515A1 (en) * | 2020-09-16 | 2023-07-26 | Complement Therapeutics Limited | Complementome assay |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| NO870613L (no) | 1986-03-05 | 1987-09-07 | Molecular Diagnostics Inc | Deteksjon av mikroorganismer i en prve inneholdende nukleinsyre. |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US5037746A (en) | 1986-12-03 | 1991-08-06 | University Patents, Inc. | RNA ribozyme polymerases, and methods |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| EP0451141B1 (en) | 1988-05-20 | 1998-11-18 | F. Hoffmann-La Roche Ag | Immobilized sequence-specific probes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5180818A (en) | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
| US20020032313A1 (en) * | 1991-03-29 | 2002-03-14 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| EP0512733A2 (en) | 1991-05-03 | 1992-11-11 | Washington University | Modified complement system regulator |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5474796A (en) | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP0655090B1 (en) | 1992-04-27 | 2000-12-27 | The Trustees Of Dartmouth College | Detection of gene sequences in biological fluids |
| JPH08505872A (ja) | 1993-01-22 | 1996-06-25 | ユニバーシティ・リサーチ・コーポレイション | 治療剤の局所化 |
| US5667969A (en) | 1993-11-12 | 1997-09-16 | University Research Corporation | Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US6706471B1 (en) | 1996-01-24 | 2004-03-16 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
| US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| GB9710475D0 (en) | 1997-05-21 | 1997-07-16 | Zeneca Ltd | Gene silencing |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| EP1068311B2 (en) | 1998-04-08 | 2020-12-09 | Commonwealth Scientific and Industrial Research Organisation | Methods and means for obtaining modified phenotypes |
| WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| WO2001006262A1 (en) | 1999-02-19 | 2001-01-25 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration |
| US20020102581A1 (en) | 1999-02-19 | 2002-08-01 | Hageman Gregory S. | Diagnostics and therapeutics for ocular disorders |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US7011952B2 (en) | 2000-02-22 | 2006-03-14 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| EP2026073B1 (en) | 2000-04-29 | 2016-03-30 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| US6632606B1 (en) | 2000-06-12 | 2003-10-14 | Aclara Biosciences, Inc. | Methods for single nucleotide polymorphism detection |
| RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| AUPR604101A0 (en) | 2001-06-29 | 2001-07-26 | Unisearch Limited | Aptamers |
| AU2002326581A1 (en) | 2001-08-10 | 2003-03-03 | University Of Virginia Patent Foundation | Enhancing the efficacy of immunotherapies by supplementing with complement |
| WO2006062716A2 (en) * | 2004-11-18 | 2006-06-15 | Yale University | Methods and compositions for treating ocular disorders |
| EP2357257B1 (en) | 2005-02-14 | 2019-07-31 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
| AU2006254979B2 (en) | 2005-06-08 | 2011-11-24 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Susceptibility genes for age-related maculopathy (ARM) on chromosome 10q26 |
| EP1943363A1 (en) | 2005-10-11 | 2008-07-16 | Yale University | Genes associated with macular degeneration |
| AU2006311966A1 (en) | 2005-11-02 | 2007-05-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method evolved for recognition and testing of age related macular degeneration (MERT-ARMD) |
| US20080146501A1 (en) | 2006-02-13 | 2008-06-19 | University Of Iowa Research Foundation | Protective complement proteins and age-related macular degeneration |
| US8012683B2 (en) | 2006-02-13 | 2011-09-06 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
| GB0611606D0 (en) * | 2006-06-13 | 2006-07-19 | Univ Belfast | Protection against and treatment of age related macular degeneration |
-
2007
- 2007-07-13 NZ NZ574046A patent/NZ574046A/xx not_active IP Right Cessation
- 2007-07-13 EP EP12152177.7A patent/EP2447275B1/en active Active
- 2007-07-13 CA CA002659392A patent/CA2659392A1/en not_active Abandoned
- 2007-07-13 AU AU2007272335A patent/AU2007272335B2/en not_active Ceased
- 2007-07-13 SG SG2011050705A patent/SG173371A1/en unknown
- 2007-07-13 EP EP12152172.8A patent/EP2479284B1/en not_active Not-in-force
- 2007-07-13 DK DK12152177.7T patent/DK2447275T3/en active
- 2007-07-13 AT AT07812932T patent/ATE551350T1/de active
- 2007-07-13 WO PCT/US2007/073514 patent/WO2008008986A2/en not_active Ceased
- 2007-07-13 JP JP2009519713A patent/JP5431151B2/ja active Active
- 2007-07-13 EP EP07812932A patent/EP2046807B1/en active Active
- 2007-08-20 US US11/894,667 patent/US7867727B2/en not_active Expired - Fee Related
-
2009
- 2009-01-01 IL IL196319A patent/IL196319A0/en unknown
-
2010
- 2010-11-24 US US12/954,425 patent/US20120040884A1/en not_active Abandoned
-
2014
- 2014-05-15 US US14/279,235 patent/US20150050646A1/en not_active Abandoned
-
2018
- 2018-03-05 US US15/912,379 patent/US20180371547A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544280A5 (enExample) | ||
| JP5431151B2 (ja) | 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬 | |
| Kerlin et al. | Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia | |
| JP2007506426A5 (enExample) | ||
| JP2004532386A (ja) | 多発性硬化症を診断および治療するためのタンパク質、遺伝子、およびこれらの使用 | |
| JP2003508022A5 (enExample) | ||
| JP7271446B2 (ja) | Ｈｌａ－ｇ転写物およびアイソフォームおよびそれらの使用 | |
| US20220017960A1 (en) | Inflammation-enabling polypeptides and uses thereof | |
| JP4779115B2 (ja) | 早期肺癌の術後予後検査方法 | |
| JP2003284574A (ja) | 核酸分子、ポリペプチド、ならびにアルツハイマー病の診断および処置を含むそれらの使用 | |
| EP2855516B1 (en) | Inflammation-enabling polypeptides and uses thereof | |
| JP2018504909A5 (enExample) | ||
| Mehdi et al. | A functional polymorphism at the transcriptional initiation site in β2‐glycoprotein I (apolipoprotein H) associated with reduced gene expression and lower plasma levels of β2‐glycoprotein I | |
| WO2016122865A1 (en) | Compositions and methods for treating age-related diabetes and related disorders | |
| CN102947446A (zh) | 肺腺癌的预后预测方法、肺腺癌的检测试剂盒以及用于治疗肺腺癌的医药组合物 | |
| Asselta et al. | Missense or splicing mutation? The case of a fibrinogen Bβ-chain mutation causing severe hypofibrinogenemia | |
| US20170072071A1 (en) | Inflammation-enabling polypeptides and uses thereof | |
| Singh et al. | Multi-exon out of frame deletion of the FBN1 gene leading to a severe juvenile onset cardiovascular phenotype in Marfan syndrome | |
| Chen et al. | von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study | |
| TWI333978B (en) | Granulysin and uses thereof | |
| JP2006516888A5 (enExample) | ||
| US20160326585A1 (en) | Inflammation-enabling polypeptides and uses thereof | |
| CN108752452B (zh) | Sars及其突变体的应用 | |
| JPWO2002026962A1 (ja) | アレルギー性疾患の検査方法 | |
| JP4471803B2 (ja) | 全身性エリテマトーデス患者血液細胞で発現亢進している遺伝子群、およびその利用 |